| Literature DB >> 26898481 |
M J H van Campenhout1, W P Brouwer1, G W van Oord1, Q Xie2, Q Zhang3, N Zhang4, S Guo2, F Tabak5, A Streinu-Cercel6, J Wang4, S D Pas7, M J Sonneveld1, R J de Knegt1, A Boonstra1, B E Hansen8, H L A Janssen9.
Abstract
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN add-on: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg).Entities:
Keywords: Chronic hepatitis B infection; entecavir; hepatitis B core-related antigen; peginterferon-alpha 2a; serum marker
Mesh：
Substances：
Year: 2016 PMID： 26898481 DOI： 10.1016/j.cmi.2016.02.002
Source DB: PubMed Journal: Clin Microbiol Infect ISSN： 1198-743X Impact factor: 8.067